OEM/ODM Manufacturer Glioblastoma Multiforme - Favipiravir CAS 259793-96-9 T-705 COVID-19 API High Quality – Ruifu

Manufacturer with High Purity and Stable Quality
Commercial Supply Favipiravir (CAS: 259793-96-9) and Related Intermediates:
Favipiravir CAS: 259793-96-9
3,6-Dichloropyrazine-2-Carbonitrile CAS: 356783-16-9
3,6-Difluoropyrazine-2-Carbonitrile CAS: 356783-28-3
6-Bromo-3-Hydroxypyrazine-2-Carboxamide CAS: 259793-88-9
3-Hydroxypyrazine-2-Carboxamide CAS: 55321-99-8
2-Aminopropanediamide CAS: 62009-47-6
Diethyl Aminomalonate Hydrochloride CAS: 13433-00-6

Package: Bottle, Aluminum foil bag, 25kg/Cardboard drum, or according to customer’s requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.

Favipiravir (T-705) (CAS 259793-96-9) is one of the 5 compounds recommended by WHO for the investigation of treatment of COVID-19.

Favipiravir (T-705) is a selective inhibitor of viral RNA-dependent RNA polymerase with activity against many RNA viruses, influenza viruses, West Nile virus, yellow fever virus, foot-and-mouth disease virus as well as other flaviviruses, arenaviruses, bunyaviruses and alphaviruses. Favipiravir is a broad-spectrum antiviral drug that was cleared by the Drugs Controller General of India (DCGI) last week for “emergency restricted” use among Covid-19 patients. Favipiravir was originally developed in the late 1990s by a company that was later purchased by the Japanese firm Fujifilm as part of its transition from the photo business to healthcare. After being tested against a range of viruses, the drug was approved in Japan in 2014 for emergency use against flu epidemics or to treat new strains of influenza.